Tuesday, January 23, 2018
 
 
Company News: Page (1) of 1 - 01/10/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
AETNA Inc. Issues Positive Coverage Decision for ThyroSeq® Thyroid Genomic Classifier
The Highly Accurate Test Provides Better Treatment Options For Aetna Insurance Plan Members
(January 10, 2018)

NEW YORK, Jan. 10, 2018 /PRNewswire/ -- ThyroSeq®, a joint partnership between UPMC and Sonic Healthcare USA, announced that Aetna has issued a positive coverage decision for ThyroSeq Thyroid Genomic Classifier.  Aetna and its more than 19 million members will now have access to ThyroSeq's highly accurate test which will result in better treatment options for patients with thyroid nodules and decrease a significant number of avoidable diagnostic thyroid surgeries.

ThyroSeq® Thyroid Genomic Classifier | Sonic Healthcare USA (PRNewsfoto/ThyroSeq)

"We are excited about the positive coverage decision and that Aetna's members will now be able to benefit from access to the ThyroSeq test," said Yuri Nikiforov, M.D., Ph.D., Professor of Pathology at University of Pittsburgh Medical Center, and principle of ThyroSeq. "The use of this test will prevent the largest number of avoidable thyroid surgeries and help to apply more individualized management to patients with thyroid nodules and cancer based on the cutting-edge genomic science." 



"This positive coverage decision for ThyroSeq Genomic Classifier by Aetna fits hand in hand with Sonic Healthcare's commitment to high quality patient care," says Jerry Hussong M.D., Chief Medical Officer of Sonic Healthcare USA.

ThyroSeq's V3® is an effective tool for a definitive diagnosis in thyroid nodules that have indeterminate fine-needle aspiration cytology, enabling the most cost-effective patient care. ThyroSeq V3 has both very high sensitivity and high specificity and therefore can be used as a "rule-out" and "rule-in" test for cancer in thyroid nodules. ThyroSeq V3 provides additional valuable prognostic information, informing the most optimal, personalized surgery for cancerous nodules.

About ThyroSeq®
ThyroSeq is a joint partnership between UPMC and Sonic Healthcare. ThyroSeq is an innovative test for thyroid nodules and cancer. With a 10-year history of continuous refinement, it incorporates all major scientific discoveries and utilizes advanced technology to provide the most accurate diagnosis of benign or malignant disease in thyroid nodules. For more information, visit ThyroSeq.com.

About Sonic Healthcare
Sonic Healthcare is one of the world's largest medical diagnostics companies. It provides comprehensive laboratory medicine/pathology services to healthcare professionals within private and public medical communities and to commercial enterprises. Headquartered in Sydney, Australia, Sonic has grown to become one of the world's leading healthcare providers with operations in USA, Australia, Germany, Switzerland, United Kingdom, Belgium, Ireland and New Zealand. Sonic's unwavering commitment is driven by the leadership team, dedicated to its patients' health and physician clients' success. For more information, please visit SonicHealthcare.com.

MEDIA CONTACT
Jeanine Wilson
(845) 548-1211
[email protected]

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/aetna-inc-issues-positive-coverage-decision-for-thyroseq-thyroid-genomic-classifier-300580855.html

SOURCE ThyroSeq

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA, Inc.,Disease,Surgery,healthcare,Surgery,Physician,Science,Medical,Cancer,Science,Medical Professionals,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines